tbuckley/cabot-search huggingface dataset:
A Key to the Electrocardiogram.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer.
Authors: Yelena Yuriy Janjigian, Marinela Capanu, Christopher M. Gromisch, David Paul Kelsen, Geoffrey Y. Ku, Karen T. Brown, Mark Schattner, David H. Ilson, David B. Solit, Michael F. Berger, Efsevia Vakiani
Journal: Journal of Clinical Oncology (2013)

e15017 Background: Trastuzumab, approved by the FDA, has been the standard of care for pts with HER2-positive EG cancer. Resistance to trastuzumab is now emerging in this population. Afatinib, an oral inhibitor of EGFR, HER2, and HER4 has potent single agent activity in HER2-positive EG cancer NCI-N87 and MSKCC patient derived xenografts (Janjigian JNM 2013). We report the initial results of a phase II study of afatinib in patients with trastuzumab refractory EG cancer. Methods: Pts with HER2 positive (IHC 3+ or FISH&gt;2.0) metastatic EG adenocarcinoma, following failure of at least one trastuzumab/chemotherapy regimen received afatinib 40 mg daily. Archival tissue from pre-trastuzumab biopsy, a new biopsy prior to the start of therapy and after 1 wk of afatinib are mandated. The primary endpoint-overall clinical benefit at 4 months: stable disease (SD), complete response (CR), or partial response (PR) by RECIST 1.1. Results: Nine patients treated with afatinib; median follow up 2.7mos (0.5 to 5.3mos). Median age 62, KPS 80, 6 males, 56% IHC3+; 44% IHC1+/2+/FISH&gt;2.0. Number of prior trastuzumab containing regimens: median 2 (1 to 4). The following treatment emergent adverse events were observed: nausea/vomiting (Grade 1/2: 22%), diarrhea (Grade 1/2:67%), fatigue (Grade1/2: 33%), rash (Grade 1/2:44%), anorexia (Grade 1/2:33%,Grade 3:11%), mucositis (Grade1/2: 11%), paronychia/nail loss (Grade 1/2:11%). To date, 7 pts evaluable for response, 3 of 7 patients (43%) derived clinical benefit; 1 pt (14%) with ongoing RECIST 1.1 confirmed PR - a durable 50% regression of biopsy proven metastases in lung and lymph nodes at 5.3 mo. A second patient had 20% tumor regression in biopsy proven liver metastasis, 3.6 mos disease stabilization. A third patient experienced 4.7 mos disease stabilization and regression of biopsy proven skin metastasis. Conclusions: Single agent afatinib shows clinical efficacy in patients with trastuzumab refractory EG cancer. The study has been expanded to accrue additional patients. Efforts to elucidate the mechanisms of trastuzumab resistance in EG cancer are ongoing. Updated molecular and clinical data will be presented. Clinical trial information: NCT01522768.
Migraine prevention with timolol. A double-blind crossover study
Authors: S. Stellar
Journal: JAMA (1984)

One hundred seven patients (77 women and 30 men) with migraine headache were given prophylactic treatment with timolol maleate, 20 to 30 mg/day, or matching placebo during a 20-week, double-blind crossover study. Among the 94 patients who completed the study, timolol was significantly better than placebo in terms of decrease in frequency of headaches from baseline, numbers of patients who had a 50% reduction in headache frequency, global response, and patient preference. Overall global response rates were 65% with timolol compared with 40% with placebo. The severity and duration of headaches that occurred were unchanged. Few side effects were reported with either timolol or placebo. The study demonstrates that the β-blocker timolol is a safe and effective treatment in patients with frequent migraine headaches. (<i>JAMA</i>1984;252:2576-2580)
Patient-physician negotiation
Authors: M. A. Benarde
Journal: JAMA (1978)

The low level of patient compliance with physician management regimens is widely recognized. Although numerous studies either have measured levels of noncompliance or have attempted to fathom the essential elements of patient-physician interaction, they do not indicate how compliance may be increased. Negotiation is a process by which two active and equal participants negotiate to obtain their respective goals (which are often at odds). Without appropriate negotiation, which requires the patient's active participation, the physician cannot hope to motivate the patient. Patients will continue to be noncompliant as long as they are treated as inferiors in the process. (<i>JAMA</i>239:1413-1415, 1978)
Gastroscopic evaluation of anti-inflammatory agents
Authors: I Caruso, G B. Porro
Journal: BMJ (1980)

assess this.We should be told how many patients receiving long-term anti-inflammatory therapy were examined in order to find the 249 patients who had no gastric lesions at the initial endoscopy, incorrectly named the pretreatment endoscopy.If few were rejected this would support the view that the lesions are often transient.We do not accept the authors' reasons for not including a control group, and would suggest the use of paracetamol in a group with osteoarthrosis.This is an important area of work in which much more information is required, but we would reluctantly question the conclusions drawn by these workers.Further studies of better design should be undertaken.
Incorrect Percentages
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Latino AIDS Awareness Day — October 15, 2015
Authors: Kristen Gray, Eduardo Valverde, Tian Tang, Azfar-E-Alam Siddiqi, ; Hall, Thomas Frieden, Harold Jaffe, Joanne Cono, Chesley Richards, Michael Iademarco, Sonja Rasmussen, Charlotte Kent, Jacqueline Gindler, Teresa Rutledge, Douglas Weatherwax, Soumya Dunworth, Teresa Hood, Jude Rutledge, Martha Boyd, Maureen Leahy, Julia Martinroe, Stephen Spriggs, Brian Wood, Moua Yang, Quang Doan, Phyllis King, Teresa Moreland, Terraye Starr, Timothy Jones, Matthew Boulton, Virginia Caine, Katherine Daniel, Jonathan Fielding, David Fleming, William Halperin, King Holmes, Robin Ikeda, Rima Khabbaz, Phyllis Meadows, Jewel Mullen, Jeff Niederdeppe, Patricia Quinlisk, Patrick Remington, Carlos Roig, William Roper, William Schaffner, Regina Simeone, Brigette Gleason, John Redd, Peter Kilmarx, Tom Sesay, Francis Bayor, Antons Mozalevskis, Allison Connolly, James Akpablie, Dimitri Prybylski, Daphne Moffett, Michael King, Micah Bass, Kristy Joseph, Jefferson Jones, Francis Ocen, Amelia Kasper, Amanda Kamali
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

National Latino AIDS Awareness Day is observed each year on October 15 to focus on the continuing and disproportionate impact of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) on the Hispanic or Latino population in the United States.Hispanics or Latinos represent approximately 17% of the U.S. population (1); however, in 2013, they accounted for 21% of all new diagnoses, corresponding to a rate of 18.7 per 100,000 (2).In 2011, an estimated 242,000 Hispanics or Latinos were living with HIV infection in the United States, representing 20% of all such persons.Of these Hispanics or Latinos, an estimated 85% had received a diagnosis of HIV infection, 40% were engaged in HIV medical care, 37% had received a prescription for antiretroviral therapy, and 31% had achieved viral suppression (3).National Latino AIDS Awareness Day is an opportunity to encourage increased HIV prevention activities, such as HIV testing, for Hispanics or Latinos.CDC supports testing, linkage to and engagement in care and treatment, and a range of other efforts to reduce the risk for acquiring or transmitting HIV infection among Hispanics or Latinos.Additional information about CDC resources and activities for National Latino AIDS Awareness Day is available at http://www.cdc.gov/Features/LatinoAIDSAwareness.Additional information about HIV among Hispanics or Latinos is available at http:// www.cdc.gov/hiv/risk/racialethnic/hispanicslatinos.Hispanics or Latinos* represent about 17% of the total U.S. population and are disproportionately affected by human immunodeficiency virus (HIV) infection in the United States (1,2).In 2013, the rate of HIV diagnosis among Hispanics or Latinos (18.7) was nearly three times that of non-Hispanic * Hispanics or Latinos can be of any race.
Genetic testing for children and adolescents. Who decides?
Authors: D. C. Wertz
Journal: JAMA (1994)

In the future there is likely to be a large array of DNA-based tests to diagnose single-gene disorders and to identify predispositions to genetically influenced disorders. This article focuses on ethical, legal, and psychological implications of testing healthy children and adolescents for such disorders. Testing may offer medical or psychological benefits but may harm parent-child bonds or the child's self-concept. Clinicians may encounter situations where they must weigh the child's or adolescent's wishes against wishes of parents. We examine the legal history and current status of minors as health care consumers; psychosocial research on their maturity to make choices; impact of testing on intrafamilial relationships; views of national commissions on appropriate ages of assent and full informed consent; ethical and legal requirements for competence in children and adolescents; and disclosure of genetic information. We propose guidelines for predictive genetic testing and counseling of children and discuss risks and benefits of testing. (<i>JAMA</i>. 1994;272:875-881)
LETTER FROM PARIS.
Authors: None A. B.
Journal: JAMA (1889)

(FROM OUR REGULAR CORRESPONDENT.) Professor Peter on the Necessity of Antiphlogistic Treatment at the Onset of Acute Pneumonia and Acute Pleurisy—Professor Lépine reports a Curious Case of Cerebral Accidents determined by a Hæmatoma and Cured by Trephining—Dr. Constantin Paul's Researches on the Action of Saccharin—Dr. Maurice Perrin. Professor Peter lately delivered a very interesting clinical lecture at the Necker Hospital, on the necessity of the antiphlogistic treatment at the onset of acute pneumonia and acute pleurisy. The lecturer said that he was induced to take up this subject owing to the neglect, now-a-days, of this precious measure in properly selected cases. If, he said, our predecessors bled to much, we have gone to the opposite extreme, much to the prejudice of the patients. He based his present lecture on a case in his ward in which the patient was affected with pleurisy accompanied with effusion, for which he was, for
The Public's Enthusiasm for Cancer Screening
Authors: Istvan Nyirjesy
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and Safety of Ipilimumab in Patients with Pretreated, Ocular Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP)
Authors: M. Maio, V. Chairion Sileni, L. Pilla, S.V.L. Nicoletti, L. Di Guardo, P. Queirolo, F. De Galitiis, M. Mandala, M. Guida, P.A. Ascierto
Journal: Annals of Oncology (2012)
P07.03 Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly-diagnosed glioblastoma
Authors: S. Burth, P. Kickingereder, D. Tichy, D. Bonekamp, A. Wick, S. Löw, M. Nowosielski, W. Wick, M. Bendszus, A. Radbruch
Journal: Neuro-Oncology (2016)
AFP is elevated more than 10 years before hepatocellular carcinoma development is detected: this observation leads to a practical risk stratification strategy
Authors: Philip Johnson, Sarah Berhane, Emily de Groot, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Shinji Satomura, Yukio Osaki, Masatoshi Kudo, Naoshi Nishida, Toru Kimura, Ruwanthi Kolamunnage-Dona, Thomas Bird, Ruben Amoros, Marta Garcia-Finana, David M Hughes
Journal: Journal of Hepatology (2020)
Impaired elimination of metronidazole in decompensated chronic liver disease.
Authors: G Farrell, N Buchanan, J Baird-Lambert
Journal: BMJ (1984)

Tissue resident memory T cells (TRM) confer protection against a variety of illnesses ranging from infections to cancers. As demonstrated in the skin, transfer of TRM from immune to naïve hosts is sufficient to prevent herpes simplex virus type 1 (HSV) associated pathology. Comparably, the presence of antigen-specific TRM in a mouse model of melanoma can limit tumor growth. In the lungs, TRM offer critical for protection against influenza, even in the absence of specific antibodies. In the skin, the functions of different CD8 T cell subsets have been linked with distinct metabolic pathways. Skin TRM display a unique metabolic profile to other CD8 memory cells subsets. They undergo enhanced fatty acid oxidation and oxidative phosphorylation as compared with circulating memory cells and naïve cells. However, it is unclear if this programming is universal between all TRM subsets and holds true in the lung. We hypothesize that lung TRM with different integrin profiles will utilize unique metabolic programs. Metabolic profiles of lung CD8 T cells were assessed using a variety of functional metabolic assays including glucose analogue uptake, fatty acid uptake, and oxidative phosphorylation as assessed by fluorescent dyes measured by flow cytometry. Nonfunctional assays including neutral lipid storage, mitochondrial mass, and mRNA transcript levels of key metabolic genes were also assessed via flow cytometry using fluorescent dyes, while transcripts were quantified via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Our findings indicate that lung TRM show enhanced fatty acid oxidation, more neutral lipid storage, and less glucose uptake than their non-TRM T cells in our influenza mouse model.
Vulvar condylomata acuminata in prepubertal females
Authors: D. A. Grace
Journal: JAMA (1967)

CONDYLOMA ACUMINATA of the vulva and periurethral regions are uncommon in children.<sup>1</sup>In general this condition tends to be misdiagnosed. Definitive diagnosis is dependent on biopsy of the lesion. We wish to report three cases seen at the Columbus Children's Hospital. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 6-year-old white girl was admitted to the hospital in February 1949, with a three-month history of a small "growth" of the vulva and persistent greenish-yellow vaginal discharge. Results from the child's physical examination were normal except for several "pedunculated warty looking growths" about 0.5 cm in diameter located adjacent to the urethral meatus. Findings from a complete blood cell count (CBC), urinalysis, and vaginal culture were normal. A general anesthetic was given and the lesions were removed with electrocautery; the microscopic examination of the tissue revealed condyloma acuminata. The postoperative course was uncomplicated and the child was discharged on the fifth postoperative
Entry to Medical School: an idle hope
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Decrease in CA-19-9 after neoadjuvant chemoradiation therapy to predict survival in locally advanced pancreatic cancer.
Authors: Jaswinder Singh, Syed Faisal Jafri, Maninder Pabla, Bradley L Freilich, Joe Cates, John M. Sheldon, David Shaeffer, Michael Connor, Raj Shah, Niharika Rath, Reed Cope, Michael Burt, Srijita Mukherjee, Unnati Parikh, Jennifer Wanpen Feeback
Journal: Journal of Clinical Oncology (2012)

e14632 Background: Carcinoma of the pancreas is among the most lethal of human cancers. Data on the overall survival rates of patients treated in the community hospital setting are limited; the purpose of this retrospective data collection study was to assess – Does CA-19-9 change during the neo adjuvant treatment of locally advanced pancreatic cancer patients predicts the overall survival (OS) at high volume community hospital setting. Methods: Eligibility included cytological or histological evidence of locally advanced unresectable and borderline resectable adenocarcinoma of the pancreas, not amenable for complete surgical resection. Their respectability was determined with EUS and CT scan / MRI and was discussed in the multi disciplinary conference. Patients diagnosed before July 2009 were essentially treated with continuous 5-FU 200 mg/m 2 for 5 weeks with radiation of 1.8 Gy per daily fraction, for a total dose of 50.4 Gy over 5.5 weeks. Patients diagnosed after July 2009 received gemcitabine 400 mg/m 2 intravenously (over 60 minutes) beginning on the first day of radiation therapy (before radiation), then weekly thereafter during radiation. Results: Data were abstracted on 64 patients (40 deceased; 24 alive) diagnosed between 6/2005 and 4/2011. The median age was 68 years (range: 41-87), and 52% were male. The majority of patients (97%) were diagnosed by endoscopic ultrasound (EUS) with biopsy. At diagnosis, 56 (88%) patients were locally advanced unresectable(without metastasis) or borderline unresectable; 49 of these had neoadjuvant treatment, and 13 were later resected. Median OS for all 64 patients was 45.4 weeks (95% CI: 29.6-61.3), with no significant differences in OS by sex of patient (p = 0.210) or smoking history (p = 0.625). Twenty-two patients (34%) had &gt;75% decreases in CA19-9 from baseline; median OS was 89.4 weeks in this group compared to 41.3 weeks in patients with changes in CA19-9 &lt;75% (p = 0.025). Conclusions: This trial demonstrates improved overall survival in patients for patients with locally advanced pancreatic cancer , who had significant decrease in CA -19-9 (&gt;75% decreases in CA19-9 from baseline) in response to neo adjuvant chemotherapy and radiation.
Correspondence
Authors: Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Osamu Yokosuka, Naoya Kato
Journal: Hepatology (2018)

1 Reply: We thank Lo et al. for their interest in our study. In our study, we evaluated the efficacy of dexamethasone in preventing fever, anorexia, and nausea/vomiting after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Indeed, we agree that several side effects after TACE may be masked or increased by the use of prophylactic dexamethasone. In fact, we found grade 3 or higher hyperglycemia in almost all patients with diabetes mellitus or impaired glucose tolerance in the dexamethasone group. Piscaglia et al. have mentioned this problem in an editorial.(1) On the other hand, steroid‐based therapy is widely used not only for the prophylactic treatment of the side effects of anticancer agents but also for the treatment of autoimmune diseases in systemic organs including the liver.(2) Several reports have already assessed adverse events associated with steroid treatment, and most physicians across the world hold this information as basic knowledge. Of note, infectious complications did not increase in those receiving a daily dose of <10 mg or a cumulative dose of <700 mg of prednisone.(4) Based on the safety results of our study, short‐term (3 days) prophylactic dexamethasone administration may increase the risk of ascites, pleural effusion, and hypertension. However, most cases in our study were manageable, and we did not find any case of serious infection. Although gastrointestinal bleeding was not observed in any patient in our study, a risk assessment of peptic ulcers using endoscopy may be advisable in some patients before administering dexamethasone and steroid treatment for other diseases.(5) As discussed in our article, the single‐center nature of our study was the main limitation; therefore, our results need to be validated in different cohorts before standardizing the use of prophylactic dexamethasone to prevent TACE‐induced postembolization syndrome. 2 Potential conflict of interest Nothing to report.